Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease
Authors
Keywords
-
Journal
BIOORGANIC CHEMISTRY
Volume 140, Issue -, Pages 106830
Publisher
Elsevier BV
Online
2023-09-06
DOI
10.1016/j.bioorg.2023.106830
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in the Omicron variant development
- (2022) Antonio Vitiello et al. JOURNAL OF INTERNAL MEDICINE
- Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
- (2022) Haozhou Tan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
- (2022) Jing Lian Suah et al. Emerging Microbes & Infections
- Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
- (2021) Yingjun Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
- (2021) Jerzy Osipiuk et al. Nature Communications
- Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
- (2021) Ewelina Weglarz-Tomczak et al. Scientific Reports
- A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease
- (2021) Stephanie Patchett et al. Cell Reports
- Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay
- (2021) Chunlong Ma et al. ACS Central Science
- Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
- (2021) Sarah Huff et al. JOURNAL OF MEDICINAL CHEMISTRY
- Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection
- (2021) Deeksha Munnur et al. NATURE IMMUNOLOGY
- Mechanisms of SARS-CoV-2 entry into cells
- (2021) Cody B. Jackson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- 6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro
- (2021) Caleb D. Swaim et al. iScience
- Understanding evolution of SARS‐CoV‐2: a perspective from analysis of genetic diversity of RdRp gene
- (2020) Sunitha M. Kasibhatla et al. JOURNAL OF MEDICAL VIROLOGY
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
- (2020) Donghyuk Shin et al. NATURE
- Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography
- (2020) Daniel W. Kneller et al. Nature Communications
- Characteristics of SARS-CoV-2 and COVID-19
- (2020) Ben Hu et al. NATURE REVIEWS MICROBIOLOGY
- Ebselen, a new candidate therapeutic against SARS-CoV-2
- (2020) C.V. Haritha et al. International Journal of Surgery
- A protein structure-guided covalent scaffold selectively targets the B1 and B2 subclass metallo-β-lactamases
- (2018) Cheng Chen et al. CHEMICAL COMMUNICATIONS
- Target discovery of ebselen with a biotinylated probe
- (2018) Zhenzhen Chen et al. CHEMICAL COMMUNICATIONS
- Ebsulfur as a potent scaffold for inhibition and labelling of New Delhi metallo-β-lactamase-1 in vitro and in vivo
- (2018) Jianpeng Su et al. BIOORGANIC CHEMISTRY
- NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine
- (2016) Nicholas C.K. Valerie et al. CANCER RESEARCH
- Ebselen as a potent covalent inhibitor of New Delhi metallo-β-lactamase (NDM-1)
- (2015) Jiachi Chiou et al. CHEMICAL COMMUNICATIONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now